Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, January 2009, p. 287-291, Vol. 53, No. 1
0066-4804/09/$08.00+0 doi:10.1128/AAC.00746-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

ko Megli
,1*
S. Koren,1
M. F. I. Palepou,2
E. Karisik,2
D. M. Livermore,2
R. Pike,2
A. Andlovic,1
S. Jeverica,1
V. Kri
an-Hergouth,1
M. Müller-Premru,1
K. Seme,1 the Slovenian ESBL Study Group
N. Woodford,2
Institute of Microbiology and Immunology, Medical Faculty, University of Ljubljana, Zalo
ka 4, 1105 Ljubljana, Slovenia,1
Antibiotic Resistance Monitoring and Reference Laboratory, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom2
Received 6 June 2008/ Returned for modification 20 August 2008/ Accepted 2 November 2008
|
|
|---|
|
|
|---|
To date, only SHV-type ESBLs have been reported in K. pneumoniae in Slovenia, and then only in one hospital (7), with no record of CTX-M ESBLs in any species. The aim of the present nationwide survey was therefore to investigate whether CTX-M-type ESBLs have now appeared in K. pneumoniae in Slovenian hospitals.
(These results were presented in part at the 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy, Munich, Germany, 2007, poster P676.)
We analyzed nonreplicate isolates of ESBL-producing K. pneumoniae from 177 patients with infections and/or colonization collected in 11 Slovenian hospitals from January 2005 to May 2006, covering almost all of the Slovenian patient population; just one microbiology department serving a small regional hospital did not participate. Identification and initial susceptibility testing results were confirmed with the Vitek 2 system (bioMérieux, Marcy l'Étoile, France) with the ID-GN and the AST-N041 test cards. ESBL production was confirmed by ESBL Etests (AB Biodisk, Solna, Sweden) with ceftazidime, cefotaxime, and cefepime strips, each with and without clavulanate. MICs were determined by Etest, with the results interpreted in accordance with CLSI guidelines (6).
CTX-M alleles were sought by a multiplex PCR assay which can detect all five major CTX-M lineages (14). blaCTX-M genes were sequenced on a CEQ 8000 (Beckmann-Coulter, High Wycombe, United Kingdom) with primers for ISEcp1 (12), with additional internal sequencing primers designed for this study (CTX-M-G1-IF [5'-AAA CTC TGC GGA ATC TGA CG-3'] and CTX-M-G1-IR [5'-TCG GTT CGC TTT CAC TTT TC-3']).
Clonal relationships were studied by pulsed-field gel electrophoresis (PFGE) of XbaI-digested genomic DNA with a CHEF DRII apparatus (Bio-Rad Laboratories, Hemel Hempstead, United Kingdom) (13). Banding patterns were analyzed with BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) with isolate clustering performed with Dice's coefficient in combination with the unweighted-pair group method using average linkages. Strains were defined as having PFGE profiles with
80% similarity.
To investigate whether plasmid transfer contributed to the spread of CTX-M ESBLs, conjugative transfer of blaCTX-M genes was studied by mating experiments on nutrient agar plates with single representatives of the major strains as plasmid donors and E. coli J53-2 pro Rifr as the recipient. Transconjugants were selected on nutrient agar plates supplemented with 2 µg/ml cefotaxime and 200 µg/ml rifampin (Sigma-Aldrich, Poole, United Kingdom) (8). Hybridization studies were performed on the same plasmids with a digoxigenin-labeled probe derived from the blaCTX-M gene sequence with the primer pair MA1/MA2 (8, 13).
Among the K. pneumoniae isolates collected in 2005 and in the first few months of 2006, we noted a statistically significant increase in the prevalence of ESBL production (P = 0.005) (Table 1). CTX-M-type β-lactamase genes were detected in 60 (34%) of the 177 ESBL-producing isolates analyzed, thus currently still representing a minority of the ESBL-producing K. pneumoniae strains in Slovenia. As in Italy and Poland (9, 10), only group 1 CTX-M enzymes were found. These were identified in 8 of the 11 participating hospitals, with a countrywide distribution (Table 1). The large difference in the prevalence of CTX-M enzymes among the eight affected hospitals (Table 1) may suggest that Slovenia is in an early stage of the dissemination of these ESBLs, as recently reported in Italy (10), or may reflect variation in the success of infection control at particular sites.
|
View this table: [in a new window] |
TABLE 1. Details of ESBL-producing K. pneumoniae isolates from 11 Slovenian hospitals
|
All isolates with blaCTX-M genes showed substantial resistance to both cefotaxime and ceftazidime (Table 2) with uniform susceptibility to imipenem. Most were multiresistant, including to ciprofloxacin and gentamicin. Variable susceptibility to amoxicillin-clavulanic acid and piperacillin-tazobactam may have reflected the presence or absence of the OXA-1 inhibitor-resistant penicillinase, which is often associated with CTX-M-15 enzymes (8). Further analysis of resistance genes encoded by CTX-M-carrying plasmids is in progress.
|
View this table: [in a new window] |
TABLE 2. Susceptibilities of major strains of K. pneumoniae producing CTX-M group 1 enzymes
|
![]() View larger version (87K): [in a new window] |
FIG. 1. Dendrogram based on PFGE typing of 60 blaCTX-M-positive K. pneumoniae isolates, in comparison with 27 blaCTX-M-negative ESBL-producing isolates, from 11 Slovenian hospitals to illustrate their relatedness. The vertical line indicates the 80% similarity score adopted to assign isolates to the same strain (unweighted-pair group method using average linkages, Dice method).
|
150-kb plasmids. The resistance phenotypes conferred by the transferred plasmids are shown in Table 3. Thus, spread of blaCTX-M-carrying plasmids to other strains of K. pneumoniae, and perhaps also to E. coli, seems likely, as reported for an epidemic CTX-M-3-encoding plasmid in Poland (1, 9). |
View this table: [in a new window] |
TABLE 3. MICs for representative isolates of the strains A, B, and C and their transconjugants
|
We thank Petra Barana
i
for technical assistance.
ka 4, 1105 Ljubljana, Slovenia. Phone: 00386 1 543 74 46. Fax: 00386 1 543 74 01. E-mail: karmen.mesko{at}mf.uni-lj.si
Published ahead of print on 10 November 2008. ![]()
The members of the Slovenian ESBL Study Group (in alphabetic order) are Jerneja Ambro
i
Avgu
tin, Department of Biology, Biotechnical Faculty, University of Ljubljana; Ingrid Berce, Public Health Care Center Nova Gorica; Marina Bujko, Institute of Public Health of the Republic of Slovenia; Jerneja Fi
er, General Hospital Dr. Franc Derganc; Tatjana Harlander, Public Health Care Center Novo Mesto; Martina Kav
i
, Public Health Care Center Koper; Slavica Loren
i
-Robnik, Public Health Care Center Maribor; Irena Piltaver, General Hospital Slovenj Gradec; Helena Ribi
, Public Health Care Center Kranj; Iztok
trumbelj, Public Health Care Center Murska Sobota; Viktorija Tomi
, University Clinic for Pulmonary and Allergic Diseases Golnik; and Tja
a
ohar-
retnik, Public Health Care Center Celje. ![]()
|
|
|---|
ek, B., A. Baraniak, T.
ohar-
retnik, A.
torman, E. Sadowy, and M. Gniadkowski. 2003. Complex endemic situation regarding extended-spectrum β-lactamase producing Klebsiella pneumoniae in a hospital in Slovenia. Microb. Drug Resist. 9(Suppl. 1):S25-S33.This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»